Induction of immune response by a replication-defective venezuelan equine encephalitis-sindbis chimeric virus replicon particle encoding an antigen
CA 2434546 C · Owner: Chiron Corporation · Inventors: Polo, John; Vajdy, Michael; O'Hagan, Derek
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A replication-defective alphavirus replicon particle containing an alphavirus vector , construct comprising a heterologous polynucleotide encoding at least one first antigen or , modified form thereof, said first antigen or modified form thereof being capable of , stimulating an immune response in a subject when administered intranasally wherein said , replication-defective alphavirus replicon particle is a chimeric alphavirus particle , containing a Venezuelan Equine Encephalitis (VEE) virus vector construct packaged with , Sindbis (SIN) virus envelope glycoproteins for use in treating a mammalian , subject by generating an immune response in the subject by intranasal administration. …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 14, 2002 and granted September 11, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 14, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 14, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.